[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frxD0JRYQYinA7Wa-MZfMBdy4LlnJvj51O7oWEDTd-GY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":48,"rows":55},"University of California, Berkeley",[4],105,false,17,4,239938,2,94,[14,17,19,22,25,27,29,31],{"name":15,"count":16},"Sleep Disorder",7,{"name":18,"count":16},"Circadian Dysregulation",{"name":20,"count":21},"Diarrhea",6,{"name":23,"count":24},"Dementia",5,{"name":26,"count":24},"Mild Cognitive Impairment",{"name":28,"count":24},"Alzheimer Disease",{"name":30,"count":9},"Overweight",{"name":32,"count":9},"Obesity",[34,39,43],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05265546","Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","2025-12-31","Psilocybin",{"nctId":40,"briefTitle":41,"date":42,"intervention":38},"NCT06367738","Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","2026-12-30",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07606625","Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment","2026-12-31","Varenicline 0.03Mg\u002FSpray Nasal Soln",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,81,110,136,162,180,208,226,244,262,287,315,342,366],{"intervention":47,"totalTrials":57,"cells":58},1,{"EARLY_PHASE1":59,"PHASE1":62,"PHASE2":64,"PHASE3":66,"PHASE4":68,"NA":79},{"trials":60,"activeCount":61},[],0,{"trials":63,"activeCount":61},[],{"trials":65,"activeCount":61},[],{"trials":67,"activeCount":61},[],{"trials":69,"activeCount":57,"soonestReadout":46},[70],{"nctId":44,"briefTitle":45,"status":71,"phases":72,"primaryCompletion":46,"completion":46,"start":73,"enrollment":74,"conditions":75,"interventions":78},"RECRUITING",[53],"2026-03-06",65,[76,77],"Dry Eye","Meibomian Gland Dysfunction",[47],{"trials":80,"activeCount":61},[],{"intervention":38,"totalTrials":11,"cells":82},{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":84,"activeCount":61},[],{"trials":86,"activeCount":11,"soonestReadout":37},[87,95],{"nctId":40,"briefTitle":41,"status":71,"phases":88,"primaryCompletion":42,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},[50],"2027-12-30","2025-11",40,[93],"Aging",[38],{"nctId":35,"briefTitle":36,"status":71,"phases":96,"primaryCompletion":37,"completion":37,"start":97,"enrollment":98,"conditions":99,"interventions":101},[50],"2024-03-08",80,[100],"Perception Disorders",[38],{"trials":103,"activeCount":61},[],{"trials":105,"activeCount":61},[],{"trials":107,"activeCount":61},[],{"trials":109,"activeCount":61},[],{"intervention":111,"totalTrials":57,"cells":112},"Daily irrigation",{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":134},{"trials":114,"activeCount":61},[],{"trials":116,"activeCount":61},[],{"trials":118,"activeCount":61},[],{"trials":120,"activeCount":61},[],{"trials":122,"activeCount":61},[123],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT03139812","Daily Irrigation With Silicone Hydrogel Contact Lens Continuous Wear","COMPLETED",[53],"2012-10-15","2012-01-15",161,[132],"Corneal Epithelial Permeability",[111],{"trials":135,"activeCount":61},[],{"intervention":137,"totalTrials":57,"cells":138},"Tolcapone",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":160},{"trials":140,"activeCount":61},[],{"trials":142,"activeCount":61},[],{"trials":144,"activeCount":61},[],{"trials":146,"activeCount":61},[],{"trials":148,"activeCount":61},[149],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":61,"conditions":156,"interventions":158},"NCT02929485","Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor","WITHDRAWN",[53],"2018-01-31","2013-07",[157],"Addiction",[137,159],"Bromocriptine",{"trials":161,"activeCount":61},[],{"intervention":159,"totalTrials":57,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":178},{"trials":165,"activeCount":61},[],{"trials":167,"activeCount":61},[],{"trials":169,"activeCount":61},[],{"trials":171,"activeCount":61},[],{"trials":173,"activeCount":61},[174],{"nctId":150,"briefTitle":151,"status":152,"phases":175,"primaryCompletion":154,"completion":154,"start":155,"enrollment":61,"conditions":176,"interventions":177},[53],[157],[137,159],{"trials":179,"activeCount":61},[],{"intervention":181,"totalTrials":57,"cells":182},"Systane Complete PF",{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":206},{"trials":184,"activeCount":61},[],{"trials":186,"activeCount":61},[],{"trials":188,"activeCount":61},[],{"trials":190,"activeCount":61},[],{"trials":192,"activeCount":61},[193],{"nctId":194,"briefTitle":195,"status":126,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},"NCT05705518","Artificial Tears, Tear Lipids and Tear Film Dynamics",[53],"2023-09-30","2024-01-30","2023-01-30",81,[76],[181,203,204,205],"Refresh Relieva PF","Refresh Optive Mega-3 PF","CVS Health Lubricant Eye Drop",{"trials":207,"activeCount":61},[],{"intervention":203,"totalTrials":57,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":224},{"trials":211,"activeCount":61},[],{"trials":213,"activeCount":61},[],{"trials":215,"activeCount":61},[],{"trials":217,"activeCount":61},[],{"trials":219,"activeCount":61},[220],{"nctId":194,"briefTitle":195,"status":126,"phases":221,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":222,"interventions":223},[53],[76],[181,203,204,205],{"trials":225,"activeCount":61},[],{"intervention":204,"totalTrials":57,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":242},{"trials":229,"activeCount":61},[],{"trials":231,"activeCount":61},[],{"trials":233,"activeCount":61},[],{"trials":235,"activeCount":61},[],{"trials":237,"activeCount":61},[238],{"nctId":194,"briefTitle":195,"status":126,"phases":239,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":240,"interventions":241},[53],[76],[181,203,204,205],{"trials":243,"activeCount":61},[],{"intervention":205,"totalTrials":57,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":260},{"trials":247,"activeCount":61},[],{"trials":249,"activeCount":61},[],{"trials":251,"activeCount":61},[],{"trials":253,"activeCount":61},[],{"trials":255,"activeCount":61},[256],{"nctId":194,"briefTitle":195,"status":126,"phases":257,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":258,"interventions":259},[53],[76],[181,203,204,205],{"trials":261,"activeCount":61},[],{"intervention":263,"totalTrials":57,"cells":264},"Atropine",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":283,"NA":285},{"trials":266,"activeCount":61},[],{"trials":268,"activeCount":61},[],{"trials":270,"activeCount":61},[],{"trials":272,"activeCount":61},[273],{"nctId":274,"briefTitle":275,"status":126,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT02870478","The Effects of Low Concentration Atropine on Pupil Size and Accommodation",[52],"2019-11-20","2016-07",32,[281],"Myopia",[263],{"trials":284,"activeCount":61},[],{"trials":286,"activeCount":61},[],{"intervention":288,"totalTrials":57,"cells":289},"Donepzil",{"EARLY_PHASE1":290,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":291,"activeCount":61},[292],{"nctId":293,"briefTitle":294,"status":126,"phases":295,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":304},"NCT05003063","Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain",[49],"2021-08-02","2021-02-04",12,[300,301,302,303],"Visual Perception","Attention","Information Processing","Cholinergic System",[288],{"trials":306,"activeCount":61},[],{"trials":308,"activeCount":61},[],{"trials":310,"activeCount":61},[],{"trials":312,"activeCount":61},[],{"trials":314,"activeCount":61},[],{"intervention":316,"totalTrials":57,"cells":317},"Tolcapone 200 MG",{"EARLY_PHASE1":318,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":319,"activeCount":61},[320],{"nctId":321,"briefTitle":322,"status":126,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":331},"NCT04205994","Dopaminergic Mechanisms Underlying Human Social Behavior",[49],"2023-12-31","2019-12-01",70,[328,329,330],"Decision Making","Executive Function","Dopamine",[316],{"trials":333,"activeCount":61},[],{"trials":335,"activeCount":61},[],{"trials":337,"activeCount":61},[],{"trials":339,"activeCount":61},[],{"trials":341,"activeCount":61},[],{"intervention":343,"totalTrials":57,"cells":344},"Nicotine gum",{"EARLY_PHASE1":345,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":346,"activeCount":61},[347],{"nctId":348,"briefTitle":349,"status":350,"phases":351,"primaryCompletion":37,"completion":37,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT05018117","Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex","UNKNOWN",[49],"2022-06-06",48,[93],[343],{"trials":357,"activeCount":61},[],{"trials":359,"activeCount":61},[],{"trials":361,"activeCount":61},[],{"trials":363,"activeCount":61},[],{"trials":365,"activeCount":61},[],{"intervention":367,"totalTrials":57,"cells":368},"Radiopharmaceuticals",{"EARLY_PHASE1":369,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":370,"activeCount":61},[371],{"nctId":372,"briefTitle":373,"status":126,"phases":374,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":380},"NCT03926702","Tau Imaging With JNJ067",[49],"2021-01-06","2019-06-18",18,[28,26,379],"Progressive Supranuclear Palsy",[367],{"trials":382,"activeCount":61},[],{"trials":384,"activeCount":61},[],{"trials":386,"activeCount":61},[],{"trials":388,"activeCount":61},[],{"trials":390,"activeCount":61},[]]